Diagnostics; making a difference

Member Press Releases

Current Articles | Categories | Search | Syndication

14 June 2016  
Study shows efficacy of Beckman Coulter DxN VERIS Molecular Diagnostics System for monitoring CMV-DNA in plasma samples
By @ 12:26 :: 179 Views

Nyon, Switzerland — (14 June 2016) Beckman Coulter is pleased to highlight results published in the Journal of Clinical Virology1 that show the company’s DxN VERIS VERIS CMV Assay is more sensitive, and the DxN VERIS Molecular Diagnostics System has greater ease-of-use benefits , than another commercially available testing system.

Read More

07 June 2016  
Excellent results reported for DxN VERIS Molecular Diagnostic System HIV-1 Assay at multiple centres across Europe
By @ 14:18 :: 144 Views


Nyon, Switzerland — (07 June 2016) Beckman Coulter is pleased to highlight the findings of a poster, presented at ECCMID, Amsterdam, 2016, regarding the analytical performance of the company’s fully automated DxN VERIS Molecular Diagnostics System and VERIS HIV-1 Assay

Read More

27 May 2016  
Multiplicom receives €1.9M grant to develop innovative liquid biopsy based cancer tests
By @ 14:00 :: 148 Views


Belgium, May 2016 - Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients. 

Read More

18 May 2016  
CEO Appointment
By @ 15:32 :: 138 Views


18 May 2016
Against the buoyant background and trajectory of the PS Biomarker Services business it is
now appropriate to expand the executive team with a senior figure strongly connected to
the pharmaceutical industry and to split the role of Executive Chairman.
Read More

18 May 2016  
Preliminary results for the year ended 31st December, 2015
By @ 09:21 :: 146 Views


18th May, 2016

 

Highlights

 

·         Turnover increased 20% to £1.88m (2014:£1.56m)

·         Licenses/Sales/Services revenue up 30% to £1.68m (2014:£1.30m)

-    Strong 51% growth in biomarker services

-    TMT® product sales rose 33% in 2015

-    Grant services £0.21m (2014: £0.27m)

·         Reduced loss after tax £2.72m (2014:£3.57m)

·         Cash at year-end £1.81m (2014:£1.87m)

·         Levels of SysQuant® /TMTcalibrator™ production doubled Q4

·         Compelling evidence in second in vivo study in Alzheimer’s that CK1d compounds reduce tau levels 

Read More

18 May 2016  
CEO Appointment
By @ 09:18 :: 131 Views


For immediate release: 18th May 2016; Cobham, UK.
Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.
Read More

16 May 2016  
OGT launches Cytocell FISH probes for glial tumours
By @ 12:37 :: 155 Views

Oxford, UK – 04 May 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours.  





Read More

13 May 2016  
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients
By @ 16:39 :: 161 Views



New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test by Hain Lifescience and a shorter, cheaper treatment regimen.

Read More

29 April 2016  
Abingdon Health Ltd announces collaboration with Sumitomo Chemical Co., Ltd
By @ 14:15 :: 155 Views

18 April 2016
Abingdon Health Ltd (“Abingdon Health”) today announces the signing of a collaboration agreement
with Sumitomo Chemical Co., Ltd (“Sumitomo Chemical”) to develop a next generation multiplexed
point of care biosensor device.
Read More

28 April 2016  
Facilitating cardiology decision-making at the point-of-care
By @ 14:28 :: 157 Views

 

As the prevalence of cardiovascular disease (CVD) continues to grow, Rhys Tassell, Point of Care Testing Team Lead at Cambridge University Hospitals NHS Foundation Trust explains how Addenbrooke’s Hospital’s Emergency Department is ensuring a swift diagnosis at the point-of-care. 

Read More

Previous Page | Next Page